Iranian Journal of Basic Medical Sciences

Iranian Journal of Basic Medical Sciences

Liquiritin ameliorates atherosclerosis in ApoE-/- mice by modulating SIRT1 and lipid metabolism

Articles in Press

Document Type : Original Article

Authors
Kang Ye
Jing Shi
Ping Gong
Zhongsheng Zhu
Department of Internal Medicine-Cardiovascular, Guangming Traditional Chinese Medicine Hospital of Pudong New Area, Shanghai 201321, China
10.22038/ijbms.2026.92111.19881
Abstract
Objective(s): Atherosclerosis (AS) and dyslipidemia are major contributors to cardiovascular disease; however, safe and effective therapeutic strategies remain limited. Liquiritin, a natural flavonoid, exhibits potential metabolic and cardiovascular benefits in human beings. This study investigated the effects of liquiritin on AS, lipid metabolism, and hepatic steatosis in high-fat diet (HFD)-induced ApoE-/- mice.
Materials and Methods: Mice were intraperitoneally administered liquiritin (20 mg/kg/day) for 12 weeks. Histological and biochemical analyses revealed that chronic liquiritin treatment did not induce hepatotoxicity, nephrotoxicity, or growth impairment, as evidenced by preserved liver and kidney architecture, unchanged serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, and blood urea nitrogen (BUN) levels, and stable body weight.
Results: Liquiritin markedly attenuated aortic root plaque formation, lipid deposition, and fibrotic areas (P<0.001) in ApoE-/- mice. Furthermore, liquiritin significantly improved serum and hepatic lipid profiles by reducing triglyceride, total cholesterol, and LDL-C levels (P<0.001) and alleviating hepatic steatosis (P<0.001), as confirmed by histological analyses. Mechanistic studies demonstrated that liquiritin restored hepatic SIRT1 expression, down-regulated PPARγ and LXRα, and up-regulated ABCA1 (P<0.001), suggesting the modulation of key lipid metabolism pathways.
Conclusion: These findings demonstrate that liquiritin protects against AS and hepatic lipid accumulation by modulating SIRT1-mediated lipid metabolism (P<0.001), emphasizing its potential as a treatment option for metabolic and cardiovascular disorders.
Keywords
Atherosclerosis
Dyslipidemia
Hepatic steatosis
Lipid metabolism
Liquiritin
SIRT1
Subjects
1. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers 2019; 5: 56.
2. Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol 2015; 209: 13-22.
3. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459-2472. 
4. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: A decade of progress. Arterioscler Thromb Vasc Biol 2004; 24: 1006-1014.
5. Kitada M, Koya D. SIRT1 in type 2 diabetes: Mechanisms and therapeutic potential. Diabetes Metab J 2013; 37: 315-325. 
6. Yu W, Fu YC, Chen CJ, Wang X, Wang W. SIRT1: A novel target to prevent atherosclerosis. J Cell Biochem 2009; 108: 10-13.
7. Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: From bench to bedside. Eur Heart J 2015; 36: 3404-3412.
8. Huang X, Wang Y, Ren K. Protective effects of liquiritin on the brain of rats with Alzheimer’s disease. West Indian Med J 2015; 64: 468-472.
9. Yang R, Yuan BC, Ma YS, Zhou S, Liu Y. The anti-inflammatory activity of licorice, a widely used Chinese herb. Pharm Biol 2017; 55: 5-18.
10. Gargiulo S, Barone V, Bonente D, Tamborrino T, Inzalaco G, Gherardini L, et al. Integrated ultrasound characterization of the diet-induced obesity (DIO) model in young adult c57bl/6j mice: Assessment of cardiovascular, renal and hepatic changes. J Imaging 2024; 10: 217.
11. Bayol SA, Simbi BH, Fowkes RC, Stickland NC. A maternal “junk food” diet in pregnancy and lactation promotes nonalcoholic Fatty liver disease in rat offspring. Endocrinology 2010; 151: 1451-1461.
12. Liu J, Han L, Zhu L, Yu Y. Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats. Lipids Health Dis 2016; 15: 27.
13. Arruda VM, Azevedo GT, Granato MJMG, Matos ACP, Araújo TG, Guerra JFDC. Oxidative stress and annexin A2 differential expression in free fatty acids-induced non-alcoholic fatty liver disease in HepG2 cells. Int J Mol Sci 2024; 25: 9591.
14. Kurien BT, Scofield RH. Western blotting: An introduction. Methods Mol Biol 2015; 1312: 17-30.
15. Wang Q, Xian M, Li C, Mi L, Ji J, Wu Z, Shi X, Han X. Protective effect of liquiritin against cisplatin-induced liver injury in mice through reduction of inflammation, oxidative stress, apoptosis and inhibition of p38 MAPK/p53 pathway based on network pharmacology and in experimental validation. J Ethnopharmacol 2025; 354:120536.
16. Jia SY, Yin WQ, Xu WM, Li J, Yan W, Lin JY. Liquiritin ameliorates painful diabetic neuropathy in SD rats by inhibiting NLRP3-MMP-9-mediated reversal of aquaporin-4 polarity in the glymphatic system. Front Pharmacol 2024; 15: 1436146.
17. Zhao Z, Wang W, Guo H, Zhou D. Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats. Behav Brain Res 2008; 194: 108-113.
18.  Salvamani S, Gunasekaran B, Shaharuddin NA, Ahmad SA, Shukor MY. Antiartherosclerotic effects of plant flavonoids. Biomed Res Int 2014; 2014: 480258.  
19. Chen Z, Zhang SL. The role of flavonoids in the prevention and management of cardiovascular complications: A narrative review. Ann Palliat Med 2021; 10: 8254-8263. 
20. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008; 283: 20015-20026.
21. Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 2014; 146: 539-549.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 20 July 2026